SMU-L11-R

Overview

SMU-L11-R is a selective TLR7 agonist with an EC 50 of 0.012 μM for human TLR7 . SMU-L11-R specifically activates TLR7 , recruits MyD88 , and triggers MAPK/NF-κB pathways, leading to TNF-α/IL-1β/IL-6 secretion in both mouse and human peripheral blood mononuclear cells. SMU-L11-R promotes M1-like macrophage polarization. SMU-L11-R exhibits excellent synergistic anti-tumor effects with PD-L1 inhibitors by upregulating CD8 + T cells. SMU-L11-R shows potential in colorectal cancer studies.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > ERK | Products > Signaling Pathways > TNF Receptor | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > MyD88 | Products > Signaling Pathways > IKK

Product Information

• Catalog No.: HY-179047
• CAS No.: 3040320-18-8
• Molecular Formula: C19H24N4O
• Molecular Weight: 324.42
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source